Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Start with 40 mg orally or intravenously twice daily. Doses may be increased as needed. Usual doses range from 40 mg to 80 mg twice daily. Doses above 80 mg/day should be divided and administered twice daily.
## Pediatric Dosing
* **Erosive Esophagitis (12 to 17 years):** 40 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (5 to 11 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (1 to 4 years):** 20 mg orally once daily for up to 8 weeks.
*Note: Dosing for younger pediatric patients or specific indications may vary and should be guided by specialist recommendations or institutional protocols.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally once daily. Intravenous administration is not recommended.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
## Key Drug Interactions
* **Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole may decrease the absorption of these drugs, leading to reduced efficacy. Avoid co-administration.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider dose reduction or interruption of pantoprazole.
* **CYP2C19 Substrates (e.g., clopidogrel):** Pantoprazole can inhibit CYP2C19, potentially affecting the metabolism of some substrates. The clinical significance for clopidogrel is debated; however, some guidelines suggest avoiding concurrent use if possible.
## Monitoring
* Monitor for signs and symptoms of fracture (especially hip, wrist, spine) with long-term use.
* Monitor for signs and symptoms of *Clostridioides difficile*-associated diarrhea.
* Monitor magnesium levels with prolonged use (typically >3 months), especially in patients taking other medications that can cause hypomagnesemia (e.g., diuretics).
* Monitor for signs of vitamin B12 deficiency with long-term use.
## Clinical Pearls
* Oral pantoprazole is generally given 30-60 minutes before a meal.
* Intravenous pantoprazole should be administered over at least 15 minutes.
* Long-term use of PPIs is associated with increased risk of *C. difficile* infection, bone fractures, hypomagnesemia, and vitamin B12 deficiency. Assess the ongoing need for acid suppression regularly.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most up-to-date and comprehensive details.*
